Pharminent · Daily Brief
September 30, 2026
Regulatory & Approvals
EMA to develop regulatory roadmap on women’s health by end of 2026
The EMA said it will develop a regulatory roadmap by the end of 2026 to change how women’s health is considered across medicines development and regulation, following a multistakeholder workshop that brought together over 100 voices on women’s health at EU and international level.
EMA →
FDA investigation leads to charges in counterfeit drug scheme
The US Attorney’s Office for the Middle District of Florida and the DOJ Criminal Division announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, in a transnational counterfeit drug distribution scheme investigated by the FDA.
FDA →
Clinical Data
uniQure shares fall on four-year Huntington’s gene therapy data
uniQure shares dropped after the company reported four-year results from the key trial supporting a potential approval of its Huntington’s disease gene therapy AMT-130, with analysts saying investors had wanted stronger durability results.
BioPharma Dive →
Lilly reports additional retatrutide data in diabetes and obesity
Eli Lilly released additional data on its triple G agonist retatrutide in diabetes and obesity.
Pharmaphorum →$LLY
Novo’s Wegovy pill maintains weight loss after switch from injections
A real-world study found that people who switched to Novo’s Wegovy pill from obesity injections continued to lose weight.
CNBC →$NVO
Orforglipron shows greater reductions than oral semaglutide in type 2 diabetes
Data presented at EASD 2026 showed orforglipron produced modestly greater weight and HbA1c reductions than oral semaglutide in type 2 diabetes.
Pharmaceutical Technology →
Deals & Partnerships
Novo to pay Hengrui up to $2.6B for once-weekly obesity pill
Novo agreed to pay Hengrui up to $2.6 billion for a once-weekly oral obesity drug.
BioPharma Dive →$NVO
AstraZeneca commits $2B to Summit Therapeutics cancer drug
AstraZeneca is making a $2 billion equity investment in Summit Therapeutics along with plans for clinical trial collaborations testing an antibody-drug conjugate combined with a PD-1/VEGF bispecific antibody in cancer.
MedCity News →$AZN
Kyowa Kirin and Knight sign Latin American deal for Poteligeo
Kyowa Kirin International signed an exclusive distribution agreement with Knight Therapeutics for mogamulizumab (Poteligeo) across selected Latin American markets.
Pharmaceutical Technology →
Business & Finance
PhRMA names Eric Cantor as chief executive officer
Former US House Majority Leader Eric Cantor has been named CEO of PhRMA, replacing Stephen Ubl.
Pharmaphorum →
Beam Therapeutics sues Chinese biotech over alleged IP theft
Beam Therapeutics filed a lawsuit alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company that struck a deal with venture capital firms.
STAT →
Tiny Health raises $33M Series B for microbiome testing
Tiny Health closed a $33 million Series B round led by B Capital, with participation from Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures, to expand microbiome testing.
MedCity News →
OBIO-backed companies pass $1B in capital raised
Life sciences and technology companies supported by OBIO’s CAAP have collectively raised more than $1 billion in capital.
Pharmaceutical Technology →
Fabrice Chouraqui steps down as CEO of Pharming
Fabrice Chouraqui is stepping down as chief executive officer of Pharming.
PharmExec →
Anthropic joins ARPA-H clinical AI effort
Anthropic is joining a clinical AI moonshot effort run by ARPA-H and will hold a closed-door health care event.
STAT →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.